The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial.

A later paper about NCT01179048. The trial’s primary report, PMID 27295427, speaks for it on the map; the numbers here are shown and do not vote.

What the trial testedas reported · 2018

Range includes no effect

Doesn’t vote: a later paper about the trial

−8%−25% to +13%

Bigger than 1 in 10 for cardiovascular events

As reported

HR 0.92, 95% CI 0.75–1.13

the abstract, start to end

… respectively; hazard ratio [HR] 0.92 [95% CI 0.75, 1.13; …

← favours treatmentfavours comparator →

could be chance

Cardiovascular events

HR 0.920.75–1.13

GLP-1 receptor agonistsCardiovascular events

1 / 3

2018

2019

2020

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it